• 1
    Hirsh J, Poller L, Deykin D, Levine M, Dalen JE. Optimal therapeutic range for oral anticoagulants. Chest. 1989; 95: 5S11S.
  • 2
    Hyers TM, Hull RD, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest. 1995; 108: 335S51S.
  • 3
    Hyers TM, Agnelli G, Hull RD, Weg JG, Morris TA, Samama M, Tapson V. Antithrombotic therapy for venous thromboembolic disease. Chest. 1998; 114: 561S78S.
  • 4
    Hirsh J, Dalen JE, Anderson DR, Poller L, Bussey H, Ansell J, Deykin D, Brandt JT. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 1998; 114: 445S69S.
  • 5
    Hirsh J, Dalen J, Guyatt G, American College of Chest Physicians. The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. American College of Chest Physicians. Chest 2001; 119 (Suppl. 1): 1S2S.
  • 6
    Cannegieter SC, Rosendaal FR, Briët E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation. 1994; 89: 63541.
  • 7
    Cannegieter SC, Torn M, Rosendaal FR. Oral anticoagulant treatment in patients with mechanical heart valves: how to reduce the risk of thromboembolic and bleeding complications. J Intern Med. 1999; 245: 36974.
  • 8
    Van Der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briët E. Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants. Thromb Haemost. 1996; 76: 126.
  • 9
    Fihn SD, Gadisseur AA, Pasterkamp E, Van Der Meer FJ, Breukink-Engbers WG, Geven-Boere LM, Van Meegen E, DeVries-Goldschmeding H, Antheunissen-Anneveld I, Van't Hoff AR, Harderman D, Smink M, Rosendaal FR. Comparison of control and stability of oral anticoagulant therapy using acenocoumarol versus phenprocoumon. Thromb Haemost 2003; 90: 2606.
  • 10
    Gadisseur AP, Van Der Meer FJ, Adriaansen HJ, Fihn SD, Rosendaal FR. Therapeutic quality control of oral anticoagulant therapy comparing the short-acting acenocoumarol and the long-acting phenprocoumon. Br J Haematol. 2002; 117: 9406.
  • 11
    Pattacini C, Manotti C, Pini M, Quintavalla R, Dettori AG. A comparative study on the quality of oral anticoagulant therapy (warfarin versus acenocoumarol). Thromb Haemost. 1994; 71: 18891.
  • 12
    Gadisseur AP, Breukink-Engbers WG, Van Der Meer FJ, Van Den Besselaar AM, Sturk A, Rosendaal FR. Comparison of the quality of oral anticoagulant therapy through patient self-management and management by specialized anticoagulation clinics in the Netherlands: a randomized clinical trial. Arch Intern Med. 2003; 163: 263946.
  • 13
    Siebenhofer A, Berghold A, Sawicki PT. Systematic review of studies of self-management of oral anticoagulation. Thromb Haemost. 2004; 91: 22532.
  • 14
    Sawicki PT. A structured teaching and self-management program for patients receiving oral anticoagulation: a randomized controlled trial. Working Group for the Study of Patient Self-Management of Oral Anticoagulation. JAMA. 1999; 281: 14550.
  • 15
    Schmitt L, Speckman J, Ansell J. Quality assessment of anticoagulation dose management: comparative evaluation of measures of time-in-therapeutic range. J Thromb Thrombolysis. 2003; 15: 21316.
  • 16
    Rosendaal FR, Cannegieter SC, Van Der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993; 69: 2369.
  • 17
    Koster T, Rosendaal FR, De Ronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet. 1993; 342: 15036.
  • 18
    Van Der Meer FJ, Koster T, Vandenbroucke JP, Briët E, Rosendaal FR. The Leiden Thrombophilia Study (LETS). Thromb Haemost. 1997; 78: 6315.
  • 19
    Koster T, Blann AD, Briët E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet. 1995; 345: 1525.
  • 20
    Van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood. 2000; 95: 28559.
  • 21
    Koster T, Rosendaal FR, Briët E, Van Der Meer FJ, Colly LP, Trienekens PH, Poort SR, Reitsma PH, Vandenbroucke JP. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood. 1995; 85: 275661.
  • 22
    Van Hylckama Vlieg A, Van Der Linden IK, Bertina RM, Rosendaal FR. High levels of factor IX increase the risk of venous thrombosis. Blood. 2000; 95: 367882.
  • 23
    Meijers JC, Tekelenburg WL, Bouma BN, Bertina RM, Rosendaal FR. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med. 2000; 342: 696701.
  • 24
    Vandenbroucke JP, Rosendaal FR. End of the line for ‘third-generation-pill’ controversy? Lancet., 1997; 349: 111314.
  • 25
    Abdollahi M, Cushman M, Rosendaal FR. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost. 2003; 89: 4938.
  • 26
    Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA. 2005; 293: 235261.
  • 27
    Wiegman H, Vossepoel AM. A computer program for long term anticoagulation control. Comput Programs Biomed 1977; 7: 7184.
  • 28
    Baglin TP, Keeling DM, Watson H, British Committee for Standards in Haematology (BCSH), Guidelines on oral anticoagulation: Guidelines on oral anticoagulation (warfarin): third edition – 2005 update. Br J Haematol. 2005; 132: 27785.
  • 29
    Palareti G, Legnani C, Cosmi B, Guazzaloca G, Cini M, Mattarozzi S. Poor anticoagulation quality in the first 3 months after unprovoked venous thromboembolism is a risk factor for long-term recurrence. J Thromb Haemost. 2005; 3: 95561.